A Phase II Trial of PD-L1 Therapy Combined With Anti-VEGF Therapy in Unresectable or Metastatic Melanoma

Inclusion Criteria: * Participants must have histologically or cytologically confirmed metastatic or unresectable stage III or IV cutaneous melanoma. * PD-L1 negative staining in at least one biopsy sample. * Age ≥ 18 years * ECOG performance status ≤ 2 (Karnofsky ≥60%, see Appendix A) * Participants may have received any number of prior therapies for treatment of their cutaneous melanoma, excluding prior treatment with anti-PD-L1 therapeutic antibodies or bevacizumab. * Participants must have measurable disease per RECIST v1.1. * Participants must have availability of a representative tumor specimen for exploratory biomarker research. * Participants must have normal organ and marrow function as defined below: * lymphocyte count ≥ 500/mcL * absolute neutrophil count ≥ 1,500/mcL without granulocyte colony-stimulating factor support * platelets\* ≥100,000/mcL * hemoglobin\* ≥9 g/dL * serum bilirubin ≤1.5 x ULN with the following exception: participants with known Gilbert's Disease: serum bilirubin level ≤ 3x ULN * AST(SGOT)/ALT(SGPT) ≤2.5 × institutional ULN, with the following exceptions: Participants with documented liver metastases: AST and ALT ≤ 5 x ULN * alkaline phosphatase (ALP) ≤2.5 × institutional ULN, with the following exceptions: * participants with documented liver or bone metastases: ALP ≤ 5 x ULN * serum creatinine ≤ 1.5 x ULN OR creatinine clearance ≥ 60 mL/min/1.73 m2 for participants with creatinine levels above institutional normal. * se…